|
Securities in F&O Ban: Sammaan Capital shares are banned from F&O trading on 1 February 2026. Key Events to Watch: Finance Minister Nirmala Sitharaman is set to table and present the Union Budget in Parliament today, while January auto sales data will be keenly watched. Result Today: Latent View Analytics will announce its quarterly earnings today. Stocks to Watch: Sun Pharmaceutical Industries has reported a 16.03% rise in consolidated net profit to Rs 3,368.81 crore on a 13.49% increase in revenue to Rs 15,520.54 crore in Q3 FY26 over Q3 FY25. Bajaj Auto's standalone net profit increased 18.68% to Rs 2,502.81 crore on an 18.84% jump in revenue from operations to Rs 15,220.33 crore in Q3 FY26 over Q3 FY25. Godfrey Phillips India reported a steady performance in Q3 FY26, with consolidated net profit after tax rising 8.7% year-on-year to Rs 343 crore, compared with Rs 316 crore in Q3 FY25. Net revenue rose 15.1% YoY to Rs 1,829 crore, compared with Rs 1,589 crore a year ago. On a consolidated basis, Meesho's net loss widened to Rs 490.68 crore in Q3 FY26, compared with a loss of Rs 37.43 crore in Q3 FY25. Net sales rose 31.32% YoY to Rs 3,517.60 crore in Q3 FY26 from Rs 2,678.64 crore in the year-ago quarter Garware Hi-Tech Films (GHFL) reported a consolidated net profit of Rs 55.77 crore in Q3 FY26, down 8.3% year-on-year, on a 1.6% decline in revenue from operations to Rs 458.74 crore compared with Q3 FY25. NTPC reported an 8.27% increase in consolidated net profit to Rs 5,597.05 crore on a 1.72% rise in net sales to Rs 45,845.68 crore in Q3 FY26 over Q3 FY25. Power Grid Corporation of India reported an 8.4% YoY rise in consolidated net profit to Rs 4,184.96 crore in Q3 FY26, compared with Rs 3,861.63 crore in Q3 FY25. Revenue from operations rose 10.3% YoY to Rs 12,395.09 crore in the quarter ended 31 December 2025. Steel Authority of India reported a 163.6% surge in consolidated net profit to Rs 374 crore on an 11.8% rise in net sales to Rs 27,371.4 crore in Q3 FY26 over Q3 FY25. AstraZeneca Pharma India said it has received approval from the CDSCO to import, sell, and distribute Durvalumab (Imfinzi) solution for infusion in 120 mg/2.4 mL and 500 mg/10 mL strengths. Durvalumab, in combination with FLOT chemotherapy as neoadjuvant and adjuvant therapy, followed by single-agent durvalumab, is indicated for adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). Powered by Capital Market - Live News
|